Product Image

Contributor Information

  • Name Mohammed Sharif
  • Institute University of Bristol

Tool Details

  • Tool name: Anti-Vitronectin V65 subunit [pAb-V65]
  • Alternate names: Complement S Protein antibody, Epibolin antibody, S Protein antibody, Serum Spreading Factor antibody, Somatomedin B antibody, Vitronectin V65 subunit antibody, VN antibody, VNT antibody, VTNC_HUMAN antibody
  • Clone: pAb-V65
  • Tool type: Antibodies
  • Tool sub-type: Primary Antibody
  • Class: Polyclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Rabbit
  • Application: ELISA ; WB
  • Description: Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum.
  • Immunogen: V65 peptide-carrier conjugate. The carrier protein is Keyhole Limpet Haemocyanin (KLH).
  • Research area: Tissue-specific biology; Immunology

  • For Research Use Only

Target Details

  • Target: Vitronectin V65 subunit
  • Target background: Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum.

Application Details

  • Application: ELISA ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

References

  •   Ourradi et al. 2017. PLoS One. 12(7):e0181334. PMID: 28715494.
  •   Development and validation of novel biomarker assays for osteoarthritis.